A new article by Fierce Healthcare titled “A new wave of middlemen offers ‘alternative funding’ for specialty drugs. Patients bear…
A new article by Fierce Healthcare titled “A new wave of middlemen offers ‘alternative funding’ for specialty drugs. Patients bear…
The 2026 Open Enrollment period is fast approaching! The 2026 Open Enrollment period for Medicare Advantage plans is October 15,…
Aimed Alliance sent a letter to Colorado Representative Ken DeGraaf regarding his special session bill, “Prescription Drug Benefit Information Transparency” (HB25B-1012).…
On October 3, the Colorado Prescription Drug Affordability Board (PDAB) voted to establish an upper payment limit (UPL) for Enbrel,…
On October 7, 2025, Aimed Alliance sent a follow-up letter to the U.S. Food and Drug Administration (FDA) regarding the…
Aimed Alliance submitted a comment to the Oregon Prescription Drug Affordability Board (PDAB) urging it to maintain a careful, evidence-based…
Aimed Alliance sent a letter to Colorado Representative Ken DeGraaf’s regarding his special session bill “Prescription Drug Benefit Information Transparency”…
On September 16, 2025, the Food and Drug Administration (FDA) issued a warning that many over-the-counter blood pressure devices lack…
Aimed Alliance has published a new resource highlighting pharmacy benefit manager (PBMs) practices and proposed reforms to ensure transparency in…
Following a May court ruling that pharmaceutical manufacturers must receive Health Resources and Services Administration (HRSA) approval before replacing upfront…